Sprycel (Dasatinib)

Dasatinib is a medicine used to treat certain types of leukemia, like Chronic Myeloid Leukemia. It works by blocking a specific protein that helps cancer cells grow. It's usually taken with other drugs.

Brand names:Sprycel
Medication

What people taking Sprycel (Dasatinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Sprycel (Dasatinib) for CML (Chronic Myeloid Leukemia)?

NameHow it went

About Sprycel (Dasatinib)

What It's For

Dasatinib, sold under the brand name Sprycel and also available as a generic, is a targeted cancer medicine for two blood cancers that share a specific genetic change called the Philadelphia chromosome. Chronic myeloid leukemia (CML) is a slow-growing cancer in which the bone marrow makes too many abnormal white blood cells. Acute lymphoblastic leukemia (ALL) is a fast-growing leukemia of lymphocytes, another type of white blood cell. Dasatinib is used only when testing shows the leukemia is Philadelphia chromosome-positive, often written Ph+. In adults, dasatinib is approved as a first treatment for newly diagnosed Ph+ CML in its chronic phase, the earlier and more stable stage of the disease. It is also approved for CML at any phase, including the more advanced accelerated and blast phases, when imatinib (Gleevec) or another earlier treatment stopped working or caused side effects a person could not tolerate. Adults with Ph+ ALL can take it after an earlier treatment failed or was not tolerated. In children 1 year and older, it treats chronic phase Ph+ CML and, together with chemotherapy, newly diagnosed Ph+ ALL. For newly diagnosed CML, dasatinib is one of several similar daily pills, alongside imatinib and nilotinib, among others. A large randomized study comparing dasatinib with nilotinib as a first treatment found no meaningful difference in how well they worked, so the choice often turns on each drug's side effects and a person's other health conditions. Phyrago is a separately approved dasatinib tablet with the same approved uses, but its instructions about heartburn medicines differ from Sprycel's, so it matters which product is dispensed.

How It Works

In Ph+ leukemia, pieces of two chromosomes swap places inside blood-forming cells, fusing two genes into a new one called BCR-ABL. That gene makes an abnormal protein, a kind of enzyme called a kinase, that keeps signaling the leukemia cells to grow and multiply. This change happens during a person's lifetime; it is not inherited. Dasatinib is a kinase inhibitor. It blocks the BCR-ABL protein, along with several related kinases, which cuts off the growth signal the leukemia depends on. Because it attaches to BCR-ABL in more than one shape, it works against many of the mutations that make leukemia stop responding to imatinib, which is why it is a common next step when imatinib fails. It does not overcome every mutation: leukemia carrying a mutation called T315I needs a different medicine. For most people with CML, dasatinib keeps the disease under control rather than removing every leukemia cell, so it is usually a long-term treatment.

Dosage & Administration

Dasatinib is a tablet taken by mouth once a day, in the morning or the evening, with or without food. Swallow the tablets whole; do not crush, cut or chew them. For adults, the usual starting dose is 100 mg a day for chronic phase CML and 140 mg a day for advanced phase CML or Ph+ ALL. Children's doses are based on body weight and are recalculated every few months as they grow. The tablets are not recommended for children who weigh less than 10 kg (about 22 pounds). The dose often changes over time. The care team may pause treatment or lower the dose to let blood counts recover or to manage other side effects, raise it if the leukemia is not responding well enough, or adjust it when a medicine that changes dasatinib levels cannot be avoided. Some specialists start at lower doses than the label; studies suggest this may work about as well with less fluid buildup and fewer low blood counts, but it has not yet been tested in a randomized trial. Take the dose prescribed for the product you were given, and do not change it on your own.

Side Effects

The most common side effects are diarrhea, nausea, headache, rash, tiredness, muscle and joint pain, and shortness of breath. Many can be managed with supportive treatment or a dose change, so stomach upset, pain or fatigue that is persistent or bothersome is worth raising with the care team rather than simply putting up with. Dasatinib also lowers blood counts, particularly in the first months and in advanced disease. Low white blood cells make infections more likely, and low platelets make bleeding more likely. Bleeding can be serious, most often in the digestive tract. Contact the care team right away for a fever or other signs of infection, or for unusual bleeding or bruising. Fluid retention is a characteristic side effect of dasatinib. Fluid can collect around the lungs (a pleural effusion) or elsewhere in the body. Contact the care team promptly for new or worsening shortness of breath, a dry cough, sharp chest pain that comes on when breathing in, swelling, or rapid weight gain. These symptoms can also be a sign of pulmonary arterial hypertension, high blood pressure in the arteries of the lungs, which is less common but can develop at any point, even after more than a year of treatment, and may improve if dasatinib is stopped. Less often, dasatinib can affect the heart, causing reduced blood flow to the heart, rhythm problems or heart-related fluid buildup, and it has been linked to brief episodes of reduced blood flow to the brain (transient ischemic attacks, sometimes called mini-strokes). Sudden chest pain or pressure or a racing or pounding heartbeat can signal a heart problem, and brief vision problems or slurred speech can signal reduced blood flow to the brain. Any of these needs emergency care right away. Rarely, it causes a severe skin reaction with blistering or peeling, which needs prompt medical attention.

Interactions & Warnings

Dasatinib needs stomach acid to be absorbed well. For Sprycel and generic dasatinib, the label says not to take proton pump inhibitors such as omeprazole or H2 blockers such as famotidine, two common types of heartburn medicine, because they can sharply reduce how much dasatinib the body takes in. If heartburn needs treatment, an antacid can be used instead, taken at least 2 hours before or 2 hours after the dasatinib dose. Phyrago's label differs: omeprazole and famotidine did not meaningfully change its levels in studies, but antacids should still be avoided or kept at least 2 hours apart from the dose. The liver breaks down dasatinib using an enzyme called CYP3A4. Medicines that strongly block this enzyme, such as the antifungal ketoconazole, and grapefruit juice can raise dasatinib levels and side effects. Medicines that strongly speed it up, such as the tuberculosis antibiotic rifampin and the herbal supplement St. John's wort, can lower levels enough to weaken treatment. These are best avoided; if one is necessary, the care team may adjust the dose. Blood thinners and medicines that affect platelets, such as aspirin, add to the bleeding risk. Have the pharmacist check any new prescription, over-the-counter medicine or supplement. Dasatinib can lengthen the QT interval, a measure of the heart's electrical cycle seen on an electrocardiogram (ECG), which can lead to rhythm problems. The risk is higher with low potassium or magnesium, an inherited long QT condition, or other medicines that prolong QT, so these are checked and corrected before and during treatment. Dasatinib can also affect the liver, so liver blood tests are part of routine monitoring, and yellowing of the skin or eyes, dark urine or belly pain should be reported to the care team right away. In children, it can affect bone growth and development, which are monitored during treatment. Dasatinib can seriously harm a developing baby. Women who could become pregnant, and men whose partners could become pregnant, should use effective birth control during treatment and for 30 days after the last dose. Anyone who becomes pregnant or thinks they might be should contact the care team. Breastfeeding is not recommended during treatment and for 2 weeks after the last dose. Anyone planning to have children should raise this with the specialist early.

What to Expect

Dasatinib treatment involves regular blood tests, especially at first. In chronic phase CML, complete blood counts are usually checked every 2 weeks for the first 12 weeks and then about every 3 months; in advanced CML or Ph+ ALL they are checked more often. Liver tests are done before starting and periodically after that. Low counts early on are common and usually recover with a short break or a lower dose. How well the treatment is working is tracked mainly with a blood test that measures the amount of BCR-ABL in the blood, often called a PCR (polymerase chain reaction) test. Specialists look for the level to fall past set milestones at about 3, 6 and 12 months. Missing a milestone may lead to checks on whether doses are being missed, testing for resistance mutations, or a change of medicine. Most people with CML stay on treatment for many years. For some who reach a very deep response and keep it for a long time, typically after at least 4 to 5 years of treatment and 2 or more years of deep response, a specialist may offer a supervised trial of stopping, called treatment-free remission. About half of people who stop dasatinib or a similar drug stay in remission. When the leukemia returns, it usually does so within the first 6 to 8 months, so PCR testing is frequent after stopping and treatment is restarted if levels rise. Stopping should only be done this way, never on your own. In Ph+ ALL, dasatinib is part of a wider treatment plan. In children with newly diagnosed Ph+ ALL, it is given alongside chemotherapy and continued for 2 years.

Questions to Ask Your Doctor

  1. 1.Why is dasatinib a good fit for me compared with imatinib, nilotinib or another option, given my other health conditions?
  2. 2.Which PCR results should we expect at 3, 6 and 12 months, and what happens if I don't reach them?
  3. 3.What should I do if I get short of breath, a cough or swelling, and how will we check for fluid around my lungs?
  4. 4.Which of my current medicines, heartburn treatments or supplements need to change, and is my product Sprycel, a generic or Phyrago?
  5. 5.Could I eventually be a candidate for stopping treatment, and what would monitoring look like if I did?

Last reviewed • Oct 2026

Educational content, not medical advice.